Welcome to our dedicated page for Cingulate news (Ticker: CINGW), a resource for investors and traders seeking the latest updates and insights on Cingulate stock.
Cingulate Inc. (NASDAQ: CING) is a clinical-stage biopharmaceutical company pioneering precision drug delivery through its Precision Timed Release™ (PTR™) platform. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical developments, regulatory milestones, and strategic partnerships.
Access real-time information about Cingulate's ADHD treatment candidates like CTx-1301, anxiety disorder therapies including CTx-2103, and global patent expansions. Our curated news collection covers FDA submissions, clinical trial results, technology licensing agreements, and financial disclosures - all critical for evaluating the company's market position.
Key updates include progress toward the mid-2025 NDA submission for CTx-1301, international patent grants, and developments in the PTR™ platform's application across therapeutic areas. Bookmark this page to stay informed about Cingulate's innovations in precision medication delivery and its impact on treatment adherence challenges.
Cingulate Inc. (NASDAQ: CING) announced that its Chairman and CEO, Shane J. Schaffer, will speak at a live Benzinga All Access event on April 18, 2023, at 10 a.m. CST. The discussion will focus on unmet needs in attention deficit/hyperactivity disorder (ADHD) and the expansion of Cingulate's Precision Timed Release™ (PTR™) platform into anxiety treatments. Schaffer will provide a company overview and recap recent clinical and business updates. The event will be available for viewing on Benzinga's YouTube channel and on Cingulate's website.
Cingulate is a biopharmaceutical company focused on developing next-generation pharmaceutical products aimed at improving treatment outcomes for patients with ADHD and potentially anxiety disorders through its PTR platform.
FAQ
What is the current stock price of Cingulate (CINGW)?
